AU2020372647B2 — Combination of a CXCR7 antagonist with an S1P1 receptor modulator
Assigned to Idorsia Pharmaceuticals Ltd · Expires 2026-02-05 · 0y expired
What this patent protects
The present invention relates to the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)- isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide: (Formula) and its use as modulator of the CXCL11/CXCL12 receptor CXCR7, especiall…
USPTO Abstract
The present invention relates to the compound (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)- isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide: (Formula) and its use as modulator of the CXCL11/CXCL12 receptor CXCR7, especially in combination with other active ingredients or therapeutic agents comprising a sphingosine-1-phosphate receptor 1 modulator (S1P1 receptor modulator) in the prevention or treatment of diseases and disorders where both CXCR7 expression or its ligands and S1P play a role. The invention further relates to pharmaceutical compositions comprising COMPOUND in combination with said other active ingredient(s) or therapeutic agent(s).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.